Cite
Llibre JM, Raffi F, Moyle G, et al. Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. PLoS One. 2016;11(7):e0159286doi: 10.1371/journal.pone.0159286.
Llibre, J. M., Raffi, F., Moyle, G., Behrens, G., Bouee, S., Reilly, G., Borg, P., Piontkowsky, D., & Rogatto, F. (2016). Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. PloS one, 11(7), e0159286. https://doi.org/10.1371/journal.pone.0159286
Llibre, Josep M, et al. "Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy." PloS one vol. 11,7 (2016): e0159286. doi: https://doi.org/10.1371/journal.pone.0159286
Llibre JM, Raffi F, Moyle G, Behrens G, Bouee S, Reilly G, Borg P, Piontkowsky D, Rogatto F. Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. PLoS One. 2016 Jul 08;11(7):e0159286. doi: 10.1371/journal.pone.0159286. eCollection 2016. PMID: 27391807; PMCID: PMC4938098.
Copy
Download .nbib
